January 2026
2025 marked a strategic inflection point for Athari BioSciences. It was the year we transitioned from platform conception into platform execution, laying out the scientific, operational, and workforce infrastructure required to support real-world immunosurveillance, biodefense, and therapeutic innovation at scale. Rather than pursuing isolated tools or single-use technologies, Athari Bio is building infrastructure-grade biological platforms: systems designed for speed, modularity, and deployment in the environments where biological insight matters most. The progress made in 2025 reflects that philosophy in action.
Advancing the Science: From Precision Tools to Operational Platforms
Biological systems change faster than the tools designed to measure them. Technologies intended to support diagnostics, therapeutics, and surveillance must function under changing targets, compressed timelines, and imperfect conditions.
In 2025, Athari Bio transitioned core technologies from precision tools into operational platforms, validating performance under conditions where adaptability, speed, and reliability are essential.
Dual-Reporter Neutralization and Cytotoxicity Platform
Our hybrid alpha-pseudovirus platform and dual-reporter assay represent a fundamental shift in how viral infectivity and cellular response can be evaluated. By integrating luminescent and fluorescent outputs into a single assay architecture, we enable simultaneous measurement of viral neutralization and cell viability within hours rather than days. This platform demonstrated strong correlation with gold-standard neutralization methods while offering substantial gains in speed, scalability, and modular adaptability. Its architecture allows rapid reconfiguration across viral targets, transforming assay development into a scalable response system capable of supporting surveillance, therapeutic evaluation, and outbreak response.
In recognition of this progress, we presented the platform at the World Vaccine Congress 2025, highlighting its potential to accelerate immunological insight across research and applied settings.
Field-Deployable Vaccine Innovation for Operational Readiness
Modern biodefense and public health response demand vaccine platforms that function beyond traditional clinical infrastructure. In 2025, Athari Bio advanced a next-generation vaccine architecture aligned with these operational realities. At the Defense Threat Reduction Agency Tech Watch, we presented a field-deployable, thermostable, needle-free oral vaccine platform designed to support rapid deployment, simplified logistics, and multivalent adaptability. This target-agnostic architecture reflects a broader strategic shift, from laboratory-optimized vaccine development toward operationally viable immunization systems capable of meeting the demands of outbreak response, remote operations, and force health protection.
Building Workforce as Infrastructure
During the Summer Internship Program, high school, undergraduate, graduate, and PhD-level trainees were embedded directly into active research and development efforts. Interns did not observe finished systems; they worked inside evolving ones.
This structure exposed trainees to real experimental timelines, data, and iterative decision-making. Learning occurred in the context of execution: troubleshooting assays under time pressure, adapting protocols as conditions changed, and understanding how individual experiments contributed to overall platform performance. The goal was not task completion, but systems fluency.
The multi-level cohort model created additional leverage. Senior trainees reinforced their own understanding by mentoring junior participants, while junior interns gained early exposure to laboratory expectations and scientific reasoning. This vertical integration increased execution capacity while building a shared technical language across experience levels.
Workforce development functioned as a force multiplier. As platforms matured, so did the internal capability to operate, extend, and translate them. Rather than separating training from research, Athari Bio treated them as coupled processes, allowing both to progress faster and with greater resilience.
Engagement in the Life Sciences Ecosystem
As Athari Bio’s platforms matured in 2025, the organization engaged more actively in regional and national life sciences conversations. These engagements reflected Athari Bio’s role not only as a research organization, but as a participant in broader discussions shaping innovation, infrastructure, workforce development, and public-private collaboration.
During the year, Athari Bio contributed to BisNow’s Mid-Atlantic Life Sciences and Biotech Summit, engaging with leaders on investment trends, regional growth drivers, infrastructure needs, and talent development. These forums provided opportunities to situate Athari Bio’s platform and workforce efforts within the wider biotechnology ecosystem and to engage with stakeholders working across research, industry, and policy.
Recognition for Excellence
Throughout 2025, Athari BioSciences received external recognition across scientific, workforce, and organizational domains and is now on track to be a key workforce development contributor for GO Virginia Region 7 by delivering training innovation and job creation. Athari Bio was named a finalist for BioBuzz’s Workforce Champion of the Year. Our organization also received a Certificate of Distinction from Loudoun County Public Schools in recognition of its contributions to developing future scientific leaders. Additionally, Athari BioSciences was recognized with a dotCOMM Award for excellence in web creativity and digital communication, underscoring the organization’s ability to effectively communicate complex scientific and workforce initiatives at scale.
Join Us
As Athari Bio enters 2026, the focus is on translating validated platforms into sustained impact. The coming year will center on expanding platform deployment, strengthening translational and commercialization pathways, and continuing to invest in the scientific and human infrastructure required to support long-term innovation at scale.
We are grateful for the collaborators, partners, researchers, and supporters who contributed to the progress achieved in 2025. That progress reflects shared commitment to building technologies that hold up under real-world conditions and deliver actionable biological insight when it matters most.
Those interested in partnering with Athari BioSciences, exploring our platform technologies, or joining the team are invited to connect and learn more:
Learn more about our science at www.athari.bio
Explore careers at www.athari.bio/careers
Follow research updates at www.athari.bio/in-the-news
The future of immunosurveillance, therapeutic development, and biosecurity will be built on platforms that are precise, adaptable, and deployable. At Athari BioSciences, we are continuing to build that future in 2026.